29 May 2026VideosRegulation & IndustryPhil Hirschhorn, Panitch Law | Erin Dunston, Panitch Schwarze | Mythili Markowski, Regeneron | Victoria Pedanou, Sanofi
WATCH: Post-grant proceedings in life sciences—strategic offense and defense in the US and Europe
Phil Hirschhorn, Partner at Panitch Law, moderates a discussion with Erin Dunston, Partner at Panitch Schwarze; Mythili Markowski, Patent Attorney at Regeneron; and Victoria Pedanou, Patent Counsel at Sanofi.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
5 November 2026 Things can go “sideways pretty quickly” if the two sides of pharma protection are not communicating with each other, said a senior panel of industry counsel at LSPN Fall.
5 November 2026 From November 1, oral proceedings before a Board of Appeal can be audio-recorded and transcribed using artificial intelligence, but any material generated will be kept internal and will not form part of the file or be made available
30 October 2026 With its goal of becoming a global life sciences leader still some way off, the UK is betting on new investment, AI and regulatory changes to help close the gap, according to the government’s autumn budget.